TABLE 1

Baseline demographics

ItemAllSEA and COPDSEAp-value
Subjects8442 (50)42 (50)
Age years61 (55–66)61 (55–65)61 (55–66)0.917
Sex
 Female34 (41)17 (41)17 (41)1.000
 Male50 (59)25 (59)25 (59)
BMI kg·m−229 (25–34)28 (25–34)29 (25–34)0.512
Therapy
 Anti-IL-5 (mepolizumab)35 (42)23 (55)12 (29)0.015#
 Anti-IL-5Rα (benralizumab)49 (58)19 (45)30 (71)
 OCS43 (51)23 (55)20 (48)0.513#
 ICS, medium–high dose100 (100)42 (100)42 (100)1.000#
IL-5 responder64 (76)32 (76)32 (76)1.000#
Smoking
 Never28 (33)0 (0)28 (67)<0.001#
 Former56 (67)42 (100)14 (33)
Pack-years20 (9–30)20 (15–30)7 (4–9)<0.001
PFT
DLCO % predicted79 (72–97)74 (70–90)94 (75–101)0.116
KCO % predicted107 (89–115)93 (80–112)112 (105–117)0.005
 FEV1/FVC post-BDT66 (54–73)66 (58–73)68 (51–73)0.785
Positive bronchodilator test21 (38)13 (43)8 (31)0.333#
Total IgE IU·mL−1177 (74–751)446 (87–1442)126 (41–259)0.040
CT imaging, mean±sd+
 Total lung volume mL5878±14796041±14615681±15150.427
 LAA-950 cc188±379271±49488±1010.113
 LAA-950 %2.8±5.23.9±6.71.4±1.60.099
Comorbidities
 Obesity (BMI ≥30 kg m−2)33 (39)36 (38)17 (41)0.823#
 CRSwNP2 (2)1 (2)1 (2)1.000#
 CRSsNP14 (17)4 (10)10 (24)0.079#
 ASA intolerance4 (5)2 (5)2 (5)1.000#
 Atopic dermatitis4 (5)1 (2)3 (7)0.305#
 Cardiovascular diseases11 (13)6 (14)5 (12)0.746#
 Diabetes3 (4)0 (0)3 (7)0.078#
 Reflux5 (6)2 (5)3 (7)0.645#
 Allergic rhinitis2 (2)0 (0)2 (5)0.152#

Data are presented as n (%) or median (interquartile range), unless otherwise stated. p-values were derived using t-test, if not indicated otherwise. SEA: severe eosinophilic asthma; BMI: body mass index; IL: interleukin; OCS: oral corticosteroids; ICS: inhaled corticosteroids; PFT: pulmonary function testing; DLCO: diffusing capacity for carbon monoxide; KCO: carbon monoxide transfer coefficient; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BDT: bronchodilator test; CT: computed tomography; LAA: low-attenuation areas; CRSwNP: chronic rhinosinusitis with nasal polyps; CRSsNP: chronic rhinosinusitis without nasal polyps; ASA: acetylsalicylic acid. #: Chi squared test; : data from n=56 patients available; +: data from n=45 patients available. Significant values are marked as bold.